No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
OssDsign AB (publ) specializes in the innovation, manufacturing, and distribution of advanced implant and material technologies crucial for bone regeneration. The company operates across a broad international market, including Sweden, Germany, the United States, the United Kingdom, the wider European region, and other global territories. Its product line features OSSDSIGN cranial, a comprehensive implant and accessory system engineered for the reconstruction of skull defects in cranioplasty procedures. Another key offering, OSSDSIGN facial, is designed to correct skeletal deformities, whether they arise from trauma or are congenital. Additionally, OssDsign provides the OSSDSIGN Cranioplug, which serves to secure bone flaps and cover burr holes, and OssDsign Catalyst, a cutting-edge nanosynthetic bone graft substitute specifically formulated to stimulate healthy bone tissue formation. Established in 2011, the company maintains its primary operational base in Uppsala, Sweden.
www.ossdsign.comNo one on the platform currently holds OSSD.ST.
No tracked institution reports a position in OSSD.ST as of their last filing.
No one on the platform has traded OSSD.ST yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 34.5% | 48.6% | ||||
| Profit Margin % | -28.3% | -130.4% | -341.7% | |||
| Free Cash Flow Margin % | -39.7% | -122.1% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $160M | -12.0% | $-0.40 | $-0.42–$-0.39 | — | 3 |
| 2027 | $229M | +43.3% | $-0.31 | $-0.34–$-0.30 | — | 3 |
| 2028 | $301M | +31.7% | $-0.12 | $-0.13–$-0.09 | — | 3 |
| 2029 | $393M | +30.5% | $0.00 | $0.00–$0.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-18 | $-0.15 | $-0.10 | +33.3% |
| 2026-05-05 | $-0.10 | $-0.10 | +0.0% |
| 2026-02-03 | $-0.17 | $-0.20 | -17.6% |
| 2025-11-04 | $-0.09 | $-0.05 | +41.8% |
| 2025-08-19 | $-0.09 | $-0.10 | -11.1% |
| 2025-05-06 | $-0.18 | $-0.15 | +17.1% |
| 2025-02-04 | $-0.13 | $-0.13 | -2.9% |
| 2024-11-12 | $-0.16 |
| $-0.10 |
| +37.5% |
| +1.00% |
| $1.3B |
| — |
| ONCO.STOncopeptides AB (publ) | $1.63 | +0.31% | $393M | — |
| PAX.STPaxman AB (publ) | $59.10 | +0.17% | $1.4B | — |
Source: Financial Modeling Prep · peers by sector/industry